Oxford Biomedica PLC Oxford BioMedica plc Director's Share Purchase (5084H)
March 16 2015 - 4:59AM
UK Regulatory
TIDMOXB
RNS Number : 5084H
Oxford Biomedica PLC
16 March 2015
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 16 March 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy company, was informed that on 13 March 2015 one of its
Directors acquired ordinary shares of 1p each ("Ordinary Shares")
as follows:
Interest after
purchase
----------- ------------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired on Shares share capital
25 November
2014
----------- ------------- ---------- ---------------- ------------ --------------
Chief
Development
Paul Blake Officer 10.25p 97,560 2,624,559 0.10%
----------- ------------- ---------- ---------------- ------------ --------------
The issued share capital of the Company is 2,567,098,228 1p
ordinary shares.
-Ends-
For further information, please
contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer Tel: +44 (0)1865
Tim Watts, Chief Financial Officer 783 000
Media Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Tel: +44 (0)20
Neal/Laura Thornton 7309 5700
Consilium Strategic Communications
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy company with an unrivalled portfolio of gene therapy
products in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Company's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Company has licenced products
and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is
available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSGIGDXUUBBGUL
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024